U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.
about
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosisCritical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosisHow could patient reported outcomes improve patient management in chronic myeloid leukemia?The Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology.Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.Alleviating anemia and thrombocytopenia in myelofibrosis patients.Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population.Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers.Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators.Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndromeEvaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial.Molecular profiling of childhood cancer: Biomarkers and novel therapiesReport of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD)Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome.Genomic and Epigenomic Alterations in CancerAACR Cancer Progress Report 2015Redox regulation of Janus kinase: The elephant in the room.Elevated viral restriction factor levels in cortical blood vessels in schizophrenia.JNK inhibitors as anti-inflammatory and neuroprotective agents.Apoptosis deregulation in myeloproliferative neoplasms.Genetic Interactions of STAT3 and Anticancer Drug Development.STAT3 inhibitors: finding a home in lymphoma and leukemia.Optimizing dosing of oncology drugs.Bone morbidity in chronic myeloproliferative neoplasms.Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.Measuring quality of life in acute myeloid leukemia: limitations and future directionsPrevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?Neuroprosthetics and the science of patient input.Myelofibrosis: an update on drug therapy in 2016.Management of myelofibrosis: JAK inhibition and beyond.Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidenceClinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.Expanding Role of Data Science and Bioinformatics in Drug Discovery and Development.Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.
P2860
Q24186554-0E1FB808-742D-4B03-A5E8-6090777A3EEFQ26996258-03F21F07-DA23-4E11-91F4-AE09540D678FQ30241092-7AC002F4-893D-45E4-B40A-4D38DD102FF4Q30964688-2AF370E5-6AAD-466F-9F6D-891C89C72DB9Q33405766-A3600333-0979-4DC3-B26A-5B5799BB8FCDQ33430113-A5FEB405-9A2C-4455-9CB6-7B41880F98C6Q33436870-31E698E2-4326-4ACB-A1E9-6DD5F2671B6BQ33652833-A147EAFB-D806-4ADD-AC90-931417138CEBQ34294698-F0460666-FEE5-42FD-A87D-A1213E55AFBFQ34361391-F3708E61-E21B-41F1-BE9E-C325C48FB784Q34434935-FC9E5634-478B-4144-9704-0C644AD20E3FQ35130847-4B1758BE-92DD-46E3-BE0C-E4DF6D0F9C5EQ35244917-5818F5BA-2024-40F3-94EA-A35BB473105AQ36250783-F7972267-F5D0-4AF9-AE80-4E844FFC4A5FQ36698172-7EA59FA8-BDCA-461F-9028-F4706B4A7F9DQ36727581-8E872C8C-9D57-4BC5-A914-3E6A615B08A9Q37057145-75F5B663-D62D-43A2-BB14-257FA0795FFCQ37210896-49064CD3-2D04-4882-BCD0-1F569AEEC9C1Q37421820-D21A2BB4-6BC8-4DD5-9C97-DA3F11A2DC4BQ37672679-EB894761-2927-42EB-AA43-A2F619643561Q38097866-1D41899C-12CE-4BF1-8A4C-5B19D1CE9B97Q38184437-69BFF05B-7AAE-465C-BA2B-3FF7C079A88BQ38198930-C5D519F5-7CD4-400D-B9B8-E9590070F8F3Q38202556-30B5B0C9-5CE1-46D6-AF3B-7433E2D81565Q38238161-1BC4002D-3225-4124-8BC1-20BC340C620CQ38513219-EB0B920B-196E-4FF8-B08E-5FA3B076F34DQ38636718-E9E057DE-7596-4BB2-88FA-15BC11F96F29Q38751230-E02A2677-7281-4EE0-A1C3-12740274F609Q38844175-F763A99E-5EC9-466E-A31A-097AFEE5ABACQ38868066-789D3D8B-2E50-4D77-A08D-DF3D1FA8443FQ38879975-0A6CD002-293C-44DD-B861-73881954C71DQ38908065-B1A9936E-AE75-45FE-9D3E-2020709FFB57Q38989215-302EEF5E-AE40-407F-8C8F-98AB232E1B0FQ39232415-962A274A-CAFA-4EB4-B9D3-43AFCEAD944DQ39554738-EA03E636-4B0A-4D5E-A178-C28B7AE914D8Q40692620-50230A59-9C22-4000-BF00-3309EFA3543FQ40996798-2545D667-2AE7-497F-8AB4-B6D9F6E9FAE5Q41490661-D256B18D-47BA-4614-92B4-4806D57D3160Q45951517-25B30910-3DC2-4E25-8ADC-38164DE73534Q45957917-4B13B033-883B-4308-94B2-30B6278863D0
P2860
U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
U.S. Food and Drug Administrat ...... e and high-risk myelofibrosis.
@ast
U.S. Food and Drug Administrat ...... e and high-risk myelofibrosis.
@en
type
label
U.S. Food and Drug Administrat ...... e and high-risk myelofibrosis.
@ast
U.S. Food and Drug Administrat ...... e and high-risk myelofibrosis.
@en
prefLabel
U.S. Food and Drug Administrat ...... e and high-risk myelofibrosis.
@ast
U.S. Food and Drug Administrat ...... e and high-risk myelofibrosis.
@en
P2093
P921
P1476
U.S. Food and Drug Administrat ...... e and high-risk myelofibrosis.
@en
P2093
Albert Deisseroth
Ann Farrell
Atiqur Rahman
Edvardas Kaminskas
Haleh Saber
Joseph Grillo
Julie Bullock
Laurie B Burke
P304
P356
10.1158/1078-0432.CCR-12-0653
P407
P577
2012-04-27T00:00:00Z